Checkpoint Therapeutics

CompanyUnited States

Checkpoint Therapeutics develops one asset, approved (cosibelimab-ipdl in metastatic cutaneous squamous cell carcinoma). Mostly antibody acting on CD274; based in the United States.

1
Asset
Furthest stage
Approved
Raised
$57.8M
2
Trials
1
Signal

Pipeline

1
  • cosibelimab-ipdl

    Blocks PD-L1 to restore antitumor immune responses.

    Approved, Antibody, CD274, metastatic cutaneous squamous cell carcinoma, locally advanced cutaneous squamous cell carcinoma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials3
  • Funding rounds and grants1
  • Deals12
  • People8
  • Signals1
  • Similar companies6

Intelligence